TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12473419
Drug: Universal drug
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal drug abuse prevention program
Study: 10544864
Drug: Loperamide HCl
Normalized name: loperamide HCl
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide HCl 0.5 mg/5 mL
Study: 6344540
Drug: Indomethacin (10(‐5)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (10(‐5) ‐ 10(‐3) moles/l)
Study: 29696920
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (acupuncture + modified formula of buzhong yiqi tang and cizhu wan)
Study: 29696920
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine group (modified formula of buzhong yiqi tang and cizhu wan only)
Study: 15356026
Drug: Pioglitazone (PIO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (PIO), 45 mg/d for 4 months
Study: 11250664
Drug: Low lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lactose milk powder (twice daily for seven weeks)
Study: 9549654
Drug: (R)-ketoprofen 100
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (R)-ketoprofen 100 mg
Study: 9549654
Drug: Acetaminophen 1,000
Normalized name: Acetaminophen 1,000mg/30mL Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1,000 mg
Study: 9549654
Drug: (R)-ketoprofen 25
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-ketoprofen 25 mg
Study: 19485584
Drug: Fluoxetine (antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (antidepressant medication)
Study: 16825684
Drug: Carbohydrate restriction
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate restriction (<120 g/d) or fat restriction (<50 g/d) during a 6-month weight-maintenance regimen
Study: 10809473
Drug: Education of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education of patients and family members about pain control, monitoring of patients' pain, and feedback about pain with treatment suggestions to nurses and physicians
Study: 2864793
Drug: mianserin 30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 30‐60 mg
Study: 2864793
Drug: clomipramine 75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: clomipramine 75‐150 mg
Study: 28441966
Drug: Tegafur-uracil maintenance
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur-uracil maintenance therapy for 1 year after adjuvant oxaliplatin-based regimen.
Study: 28441966
Drug: Observation arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation arm (no treatment).
Study: 18347654
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/d for 7-9 days)
Study: 17009837
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg telmisartan
Study: 12713080
Drug: 25 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mmol/L bicarbonate/10 mmol/L lactate peritoneal dialysis solution
Study: 12713080
Drug: 35 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mmol/L lactate solution
Study: 10669364
Drug: Hydroxyurea (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (500 mg/day)
Study: 3539129
Drug: Homeopathic drug
Normalized name: homeopathic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic drug preparation C (i.v. injections over 5 days)
Study: 3539129
Drug: Homeopathic drug
Normalized name: homeopathic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic drug preparation D (i.v. injections over 5 days)
Study: 3539129
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (i.v. injections over 5 days)
Study: 31608930
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion (1 pmol/min × kg)
Study: 29526831
Drug: Dexketoprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen (50 mg in 100 mL normal saline)
Study: 29526831
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g in 100 mL normal saline)
Study: 22551385
Drug: Full guided
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full guided implant surgery (template based guided cavity preparation and guided implant insertion)
Study: 22551385
Drug: Half-guided implant
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-guided implant surgery (template based guided cavity preparation and free-handed, manual implant insertion)
Study: 18454662
Drug: Minocycline microspheres
Normalized name: minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline microspheres (1 mg)
Study: 1543376
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (Desmospray) for one month
Study: 1543376
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (Desmospray) for three months
Study: 24867512
Drug: Colinox® (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colinox® (combination of Simethicone and Bacillus coagulans)
Study: 20647174
Drug: Elimination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elimination diet based on IgG antibodies
Study: 17875547
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) standard dose (10 mg/m2/week)
Study: 17875547
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) higher dose (15 mg/m2/week or 30 mg/m2/week)
Study: 24625546
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS treatment
Study: 24500112
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (20 g L(‐1))
Study: 19284927
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg (for subjects aged >or=65 years)
Study: 19284927
Drug: Ramelteon 16
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 16 mg (for subjects aged 18 to 64 years)
Study: 17975239
Drug: Multiple-injection technique
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-injection technique for sciatic and femoral blocks
Study: 11968894
Drug: Noncontact radiant
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact radiant warming device with offloading therapy
Study: 11968894
Drug: Offloading therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Offloading therapy only
Study: 19033449
Drug: Lercanidipine (LER)
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine (LER) 20 mg
Study: 19033449
Drug: Fluvastatin (FV)
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin (FV) 40 mg
Study: 19033449
Drug: Lercanidipine (LER)
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine (LER) 20 mg + Fluvastatin (FV) 40 mg
Study: 17577037
Drug: HD-FU (3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-FU (3,000 mg/m2/24 hours)
Study: 17577037
Drug: HD-FU/FA (2,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-FU/FA (2,600 mg/m2/24 hours plus dl-FA 500 mg/m2 or l-FA 250 mg/m2)
Study: 17577037
Drug: HD-FU/FA/Cis (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-FU/FA/Cis (2,000 mg/m2/24 hours plus FA plus biweekly Cis 50 mg/m2)
Study: 8020527
Drug: Iomeprol contrast
Normalized name: iomeprol
DrugBank: Iomeprol (DB11705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol contrast medium at concentrations of 150, 200, 250, 300, 350, and 400 mgI/ml
Study: 2499037
Drug: Interferon alpha-2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha-2b, Introna, 3 MU 3 times weekly subcutaneously
Study: 1130437
Drug: Antihypertensive medications
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medications (both groups)
Study: 20146881
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFA) 2 g/day for 3 months
Study: 17156509
Drug: Propofol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (intravenous anaesthetic)
Study: 10349437
Drug: Inactivated and
Normalized name: hepatitis A inactivated and hepatitis B (recombinant) vaccine per 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated and trivalent vaccine containing strains of Leptospira canicola, icterohaemorrhagiae and pomona
Study: 2752395
Drug: Diphenylhydantoin (2‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenylhydantoin (2‐3 mg/kg/day for 6 months)
Study: 177474
Drug: daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily prednisone therapy
Study: 177474
Drug: daily methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily methylprednisolone
Study: 177474
Drug: alternate-day therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: alternate-day therapy
Study: 31646668
Drug: 7-day ibuprofen
Normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day ibuprofen group (600 mg three times a day, N=29)
Study: 31646668
Drug: 3-day ibuprofen
Normalized name: ibuprofen 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day ibuprofen group (N=30)
Study: 28844816
Drug: Guadecitabine 60
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 60 mg/m2 on a 5-day schedule
Study: 28844816
Drug: Guadecitabine 90
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 90 mg/m2 on a 5-day schedule
Study: 28844816
Drug: Guadecitabine 60
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 60 mg/m2 on a 10-day schedule
Study: 28844816
Drug: Guadecitabine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine (all doses and schedules)
Study: 24260516
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of contrast medium (Group I)
Study: 24260516
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of contrast medium (Group II)
Study: 20584756
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid and Trendelenburg position (OT)
Study: 20584756
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid (IV)
Study: 15314548
Drug: 5'‐DFUR (Furtulon)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR (Furtulon) 800 mg/d for 2 years
Study: 10838236
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 500 ml
Study: 10838236
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 1000 ml
Study: 8468435
Drug: Moclobemide (150-525
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150-525 mg/day, mean 307 mg during last week)
Study: 8468435
Drug: Imipramine (50-175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50-175 mg/day, mean 100 mg during last week)
Study: 3702577
Drug: Dapsone 1
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 1 mg/kg body weight/day
Study: 3702577
Drug: Dapsone 4
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone 4 mg/kg body weight/day
Study: 3702577
Drug: Dapsone treatment
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone treatment (both dosages)
Study: 3076782
Drug: bezafibrate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (600 mg daily)
Study: 30657017
Drug: Portable fibrobronchoscopy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portable fibrobronchoscopy treatment
Study: 30657017
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine sputum suction, anti-infection drugs, sputum-reducing drugs)
Study: 25046032
Drug: Pelvic plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic plexus block (PPB) with 2.5 mL 2% lignocaine injection bilaterally along with intrarectal local anaesthesia (IRLA) with 10 mL 2% lignocaine jelly
Study: 25046032
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block (PNB) along with intrarectal local anaesthesia (IRLA) with 10 mL 2% lignocaine jelly
Study: 14992883
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg/daily)
Study: 14992883
Drug: Sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (80 mg twice daily)
Study: 11843924
Drug: Antiseptic cream
Normalized name: LANTISEPTIC CREAM,TOP
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseptic cream applied to the nose twice daily for 4 weeks
Study: 10546408
Drug: Rifaximin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (5 ml, equal to 100 mg, x 4/day for 3 days on average)
Study: 10546408
Drug: Neomycin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin + bacitracin (5 ml x 4/day for 4 days on average)
Study: 8044619
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation (n = 89)
Study: 8044619
Drug: No bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bowel preparation (n = 97)
Study: 2903762
Drug: Mifentidine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 2.5 mg
Study: 2903762
Drug: Mifentidine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 5 mg
Study: 2903762
Drug: Mifentidine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 10 mg
Study: 2903762
Drug: Mifentidine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 10 mg (multiple dosing for 14 days)
Study: 2903762
Drug: Mifentidine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 20 mg (multiple dosing for 14 days)
Study: 2903762
Drug: Mifentidine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine (both doses)
Study: 23865657
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie recommendations
Study: 21360507
Drug: Modified-release sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release sildenafil 200 mg once daily for 25 days
Study: 12575565
Drug: Xianlong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xianlong Capsule (XLC)
Study: 7838516
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day, then 100 mg for 6.8 days)
Study: 7838516
Drug: Ofloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (100 mg twice a day for 8.0 days)
Study: 3283356
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg IV-methylprednisolone
Study: 3283356
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg IV-methylprednisolone
Study: 3283356
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg IM-methylprednisolone
Study: 9219316
Drug: meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 7.5 mg and 15 mg
Study: 7932124
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 0.1% (Voltaren) solution
Study: 2905149
Drug: Propranolol (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40, 80 and 160 mg)
Study: 26987871
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group, n=7)
Study: 24325147
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg simethicone suspension in 5 mL water
Study: 24325147
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg simethicone suspension in 100 mL water
Study: 24325147
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg simethicone suspension in 100 mL water containing 200 mg N-acetylcysteine
Study: 19748613
Drug: Endoscopic‐guided aerosolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic‐guided aerosolized spray (EGAS)
Study: 18406179
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (H)
Study: 18406179
Drug: Heparin reversed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin reversed with protamine (H+P)
Study: 29653686
Drug: Pegvaliase 20
Normalized name: pegvaliase 20 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvaliase 20 mg/day
Study: 29653686
Drug: Pegvaliase 40
Normalized name: PEGVALIASE
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegvaliase 40 mg/day
Study: 29653686
Drug: Pegvaliase (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvaliase (varied doses from 5 mg/day to 60 mg/day)
Study: 24861503
Drug: Ezetimibe-Simvastatin (E-S)
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe-Simvastatin (E-S) 10/40 mg
Study: 24861503
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Rosuvastatin 20 mg
Study: 16875813
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) delivered by HFA‐227 metered dose inhaler (MDI) 400 microg bid
Study: 16875813
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) delivered by HFA‐227 metered dose inhaler (MDI) 800 microg bid
Study: 16875813
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) treatment
Study: 11884789
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of contrast material (Ioversol 320) only (Group A)
Study: 11884789
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of contrast medium pushed with 6 ml saline (Group B)
Study: 11884789
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of contrast medium pushed with 12 ml saline (Group C)
Study: 11884789
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of contrast medium pushed with 25 ml saline (Group D)
Study: 11884789
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of contrast medium pushed with 50 ml saline (Group E)
Study: 7916913
Drug: Buprenorphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (1 mg, intramuscularly)
Study: 30872104
Drug: Oral viscous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral viscous budesonide (OVB) 1 mg/4 mL twice daily
Study: 30872104
Drug: Fluticasone MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone MDI 880 μg twice daily
Study: 28656805
Drug: Methylphenidate (MPH),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (MPH), single dose, 10 mg
Study: 18076218
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg twice daily for 6 days and once on day 7
Study: 18076218
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate with pantoprazole 40 mg twice daily starting 2 days prior to dabigatran administration
Study: 14559386
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered allopregnanolone gel during the last 10 days of the second cycle (group 1)
Study: 14559386
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered allopregnanolone gel during the last 10 days of each cycle (group 2)
Study: 3533126
Drug: Methylprednisolone (84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (84 mg total over 4 days, starting with 24 mg 2 hours after surgery)
Study: 3533126
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g at 2, 6, and 9 hours after surgery, then 500 mg four times daily for the next 2 days)
Study: 24363128
Drug: CyA MEPC
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA MEPC 2-3 mg/kg BW once a day before breakfast
Study: 24363128
Drug: CyA MEPC
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA MEPC 1.5 mg/kg BW twice a day before meals
Study: 24363128
Drug: CyA MEPC
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA MEPC 2-3 mg/kg BW once a day (C2 ≥600 ng/mL)
Study: 24363128
Drug: CyA MEPC
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA MEPC 1.5 mg/kg BW twice a day (C2 ≥600 ng/mL)
Study: 20886571
Drug: Standard-dose pregabalin/tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose pregabalin/tolterodine ER (150 mg BID/4 mg QD)
Study: 20886571
Drug: Pregabalin alone
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin alone (150 mg BID)